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doi:10.1016/j.jmii.2010.02.004Background: Antimicrobial resistance is a major health problem worldwide. We evaluated the
antimicrobial resistance trends of 16 major bacterial pathogens at a tertiary medical center in
northern Taiwan.
Methods: We conducted a retrospective review of annual summary documents for antimicro-
bial susceptibility of clinically isolated gram-positive and gram-negative bacteria from 1985
to 2005. The numbers of isolates and susceptibilities were calculated for three 7-year periods:
first period, 1985e1991; second period, 1992e1998; and the third period, 1999e2005.
Results: During the 21-year period, 219,715 bacterial pathogens were identified. A significant
increase in incidence over time was found for methicillin-resistant Staphylococcus aureus,
methicillin-resistant S epidermidis, penicillin-nonsusceptible Streptococcus pneumoniae, eryth-
romycin-resistant S pneumoniae, vancomycin-resistant enterococci, cefotaxime/ceftriaxone-
resistant Escherichia coli and Klebsiella pneumoniae, and imipenem-resistant Acinetobacter
baumannii. Additionally, a significant increase in ciprofloxacin resistance rates over time from
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132 W.-T. Lo et al.2005). However, a significant decrease in erythromycin resistance rate with time from 1999 to
2005 was found for Groups A and B streptococci, non-A, B, D streptococci, and S pneumoniae.
Conclusion: Resistance to antimicrobial agents increased rapidly in the past two decades in
Taiwan and has become very common in major bacterial pathogens. Continuous enforcement
of policies to limit use of antimicrobial agents and active surveillance of antimicrobial resistance
through a nationwide system are both warranted.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Antimicrobial resistance is an increasing threat to patients in
health care settings aswell as in the community, andmortality
and morbidity from infection are greater when caused by
antimicrobial-resistant bacteria.1e4 Taiwan has one of the
highest levels of antimicrobial resistance in the world, and
previous studies in Taiwan clearly demonstrated the remark-
ablyhighprevalenceof somecritically resistantbacteria, such
as methicillin-resistant Staphylococcus aureus (MRSA), peni-
cillin-nonsusceptible Streptococcus pneumoniae (PNSSP),
macrolide-resistant streptococci, third-generation cephalo-
sporin-resistant Enterobacteriaceae, imipenem-resistant
Pseudomonas aeruginosa, Acinetobacter baumannii, and
ciprofloxacin-resistant Enterobacteriaceae.5e13 Importantly,
understanding the hospital antibiogram is mandatory in
solving the problem of antimicrobial resistance in hospitals.14
In the past, over-the-counter antibiotic use as well as
the widespread use of antimicrobial agents in animal
husbandry spurred the rapid emergence of resistant
bacteria in Taiwan.5,15 Since 1995, medical payments have
been regulated by the National Health Insurance System
and a restrictive governmental policy to deny reimburse-
ment through the National Health Insurance System for the
costs of antibiotics used for the treatment of acute upper
respiratory tract infections without evidence of bacterial
involvement was implemented in 2001.16 In addition, many
other measures to control resistance problems were insti-
tuted in Taiwan, including more rigorous enforcement of
prescription-filling practices in the pharmacy (starting in
1997), educational programs about appropriate antibiotic
use for physicians and patients (starting in 1998), prohibi-
tion of several antimicrobial agents (such as avoparcin,
kanamycin, and spiramycin) in animal husbandry by the
Council of Agriculture in 2000, and antibiotic interventions
were implemented in most hospitals in recent years.5,16
To understand the prevalence and trends of antimicro-
bial resistance among major bacterial pathogens in the past
two decades in Taiwan, a retrospective review of the
annual summary documents for antimicrobial susceptibility
of clinically isolated gram-positive and gram-negative
bacteria (GNB) from 1985 to 2005 in Tri-Service General
Hospital (TSGH) were retrieved.
Methods
Setting
TSGH, a tertiary care medical center located in Taipei city,
northern Taiwan, had 1,200 beds in 1985 and 1,700 beds in2005. The entire hospital moved to new facilities in 2000,
with less crowding and larger interbed space, and a smaller
proportion of intensive care unit beds to general ward beds.
The Nosocomial Infection Control Committee of the hospital
was established in 1984. Before 1999, no specific and well-
established antibiotic control policies were implemented at
the hospital. All attending physicians at the hospital pres-
cribed nearly all antimicrobial agents without consultation
with hospital infectious disease specialists.
Data collection
All clinical specimens for bacterial growth and isolation were
sent to the central laboratory in the department of clinical
pathology at TSGH. These specimens included those from
hospitalized in-patients, patients in the emergency services,
and patients in the outpatient clinics of all services. In this
analysis, there were totally 16 major bacterial pathogens
studied, including S aureus, coagulase-negative staphylo-
cocci (focus on S epidermidis), S pneumoniae, other strep-
tococci (including Groups A and B streptococci, non-A, B, and
D streptococci and viridans streptococci), Enterococcus sp
(including E faecalis and E faecium), Escherichia coli, Kleb-
siella pneumoniae, Proteusmirabilis, Enterobacter sp (focus
on E cloacae), Serratia marcescens, P aeruginosa, and Aci-
netobacter sp (focus on A baumannii). These isolates were
nonduplicate samples, as several isolates of one species from
each patient recovered within 7 days were considered one
isolate. Isolates were identified by standard methods and
were confirmed using Vitek or API products (bioMerieux Vitek
Inc., Hazelwood, MO, USA). The numbers of isolates were
calculated for three 7-year periods: first period, 1985e1991;
second period, 1992e1998; and the third period, 1999e2005.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing of the 16 major bacte-
rial pathogens was performed by the disk-diffusion method.
Isolates were classified as susceptible or resistant (including
intermediate category) by the annually renewed Clinical
Laboratory Standards Institute (CLSI; formerly known as the
NCCLS) guidelines.17,18 Screening for extended-spectrum
b-lactamase (ESBL) phenotypes among K pneumoniae and
E coli began in 2005. Isolates displaying positive double-disk
synergy were considered ESBL producers. Double-disk
confirmatory tests were performed using cefotaxime,
cefotaxime-clavulanate, ceftazidime, and ceftazidime-
clavulanate to confirm the ESBL phenotype.17 The antimi-
crobial susceptibilities were summed for each of the 7-year
periods indicated above.
Table 1 Year of approval of selected antimicrobial agents
at Tri-Service General Hospital
Antimicrobial agent Year of approval
Erythromycin 1970
Oxacillin 1972
Gentamicin 1983
Cefotaxime 1984
Vancomycin 1984
Amikacin 1987
Ceftazidime 1989
Imipenem 1989
Ciprofloxacin 1991
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isolates were not categorized by coagulase negativity and
positivity until 2004; isolates of Streptococcus sp other than
S pneumoniae were represented as “other streptococci”
before 1997; isolates of Group A streptococci; viridans
streptococci; Group B streptococci; and non-A, B, and D
streptococci were separated from “other” streptococcal
isolates since 1999. In addition, since 1997, isolates of E
cloacae were separated from Enterobacter sp and isolates
of A baumannii were similarly separated from Acineto-
bacter sp. E faecalis and E faecium isolates were separated
from Enterococcus sp when they were isolated from
expectedly sterile sites after 1999.
Trends in resistance
To determine the secular resistance trends of major
bacterial pathogens at TSGH, the disk-diffusion suscepti-
bility data of these organisms were retrieved from 1985 to
2005 annual summary documents. To calculate the resis-
tance rates, isolates of each species with identical resis-
tance profiles recovered from one patient within 7 days
were counted as one isolate.
Statistical analysis
Pearson’s correlation coefficient was used to determine the
relationship between time series and resistance trends.
Annual trends of resistance to each antimicrobial agent for
each of the 16 bacteria studied were calculated using
Durbin-Watson statistics. An r value greater than 0.72 (or
less than 0.72) and a p value less than 0.05 were consid-
ered statistically significant.
Results
Resistance rates
Table 1 shows the years when the selected antibiotics were
approved at TSGH. During the 21-year period, 219,715
bacterial pathogens were identified. The sums of isolates
by genus and species and antimicrobial susceptibilities of
gram-positive bacteria and gram-negative bacteria (GNB)
for each of the three 7-year periods are shown in Tables 2
and 3, respectively. Among S aureus isolates, the resis-
tances to methicillin, clindamycin, cephazoline, erythro-
mycin, and gentamicin were high (75%) and increased
substantially after the first period (1985e1991). Vancomy-
cin remained the most active agent for clinical S aureus
isolates. For S epidermidis isolates, the high prevalence of
antimicrobial resistance was as the same as that of S
aureus. Furthermore, susceptibilities to penicillin, ampi-
cillin, clindamycin, and erythromycin among S pneumoniae
isolates remained low and decreased proportionally after
the first period. During the third period (1999e2005),
resistance to penicillin, clindamycin, and erythromycin
were 75.6%, 67.3%, and 92.0%, respectively. All clinical
S pneumoniae isolates were susceptible to vancomycin. In
contrast to S pneumoniae, the antimicrobial susceptibilities
of other streptococci did not decrease after the firstperiod. Of the enterococci, 10%e17% was resistant to
ampicillin and 63.9% were resistant to high-level genta-
micin in the third period. The rate of vancomycin resistance
was 22% during the third period. Additionally, E faecalis
isolates were resistant to ampicillin (2.4%), vancomycin
(5.2%), and high-level gentamicin (67.3%); E faecium
isolates were much more resistant to ampicillin (83.7%),
vancomycin (27.5%), and high-level gentamicin (79.1%).
Both E coli and K pneumoniae isolates were highly
resistant to cefazolin and gentamicin (Table 3). Increasing
resistance to third-generation cephalosporins was observed
among these isolates throughout the three periods. P mir-
abilis isolates were highly susceptible to third-generation
cephalosporins, amikacin, imipenem, and aztreonam
(>95%). In contrast, Enterobacter isolates (including E
cloacae) were less susceptible to third-generation cepha-
losporins, amikacin, and aztreonam (46.4e89.5%), whereas
susceptibility to imipenem remained high (>98%). Although
S marcescens and P aeruginosa isolates remained suscep-
tible to ceftazidime (>90% and >80%, respectively),
resistance to ceftazidime was increasing among both
pathogens. In the third period, the overall rate of resis-
tance to imipenem was 4.8% for A baumannii and 16.8% in P
aeruginosa. Thus, imipenem was the most active agent for
the GNB isolates tested during the study period. Addi-
tionally, based on the CLSI guidelines for ESBL confirmation
testing,17 the percentage of ESBL-producing K pneumoniae
(307/1,858, 16.5%) was greater than that for E coli (182/
3,326, 5.4%) in 2005.
Resistance trends
Figure 1 shows the secular trends for MRSA, methicillin-
resistant S epidermidis (MRSE, until 2003), PNSSP, eryth-
romycin-resistant S pneumoniae (ERSP), vancomycin-
resistant enterococci (VRE, since 1988), and high-level
gentamicin resistant enterococci (HLGRE, since 1999). The
secular trends for MRSA, MRSE, PNSSP, ERSP, and VRE
increased significantly with time (r> 0.72 and p< 0.001).
Peak prevalence for MRSA and ERSP occurred in 2000 and
decreased significantly over time during the period of
2000e2005 (r<0.72 and p< 0.05). The prevalence of
ERSP and HLGRE remained steadily high throughout the
studying period. Additionally, the secular trend of various
streptococci with erythromycin resistance from 1999 to
2005 is shown in Fig. 2. Erythromycin resistance declined
significantly in Groups A and B streptococci; non-A, B, and D
Table 2 Antimicrobial susceptibility rates of common clinical gram-positive bacteria at Tri-Service General Hospital from 1985
to 2005
Pathogen Period Number
of isolates
Antimicrobial susceptibility (%)
P AM OX CC CZ E GM VA
Staphylococcus aureus 1985e1991 4,455 2.2 2.4 68.6 76.0 d 47.3 66.5 100
1992e1998 14,098 0.7 0.7 21.5 25.6 d 15.5 22.6 100
1999e2005 24,976 0.3 d 21.8 23.2 d 17.9 28.9 100
Staphylococcus
epidermidis
1985e1991 3,283 6.5 6.9 42.8 77.6 d 45.4 44.9 100
1992e1998 3,487 5.5 5.4 28.7 57.3 d 29.6 39.1 100
1999e2003 1,522 2.0 d 16.9 40.4 d 21.7 25.5 100
Coagulase-negative
staphylococci
2002e2005 3,093 1.1 d 22.3 50.5 d 33.3 39.6 100
Streptococcus
pneumoniae
1985e1991 78 100 98.7 90.3 89.0 d 75.7 25.8 100
1992e1998 179 60.6 60.1 d 49.2 d 25.5 28.9 100
1999e2005 610 24.4 24.4 d 32.7 d 8.0 d 100
Other streptococci 1985e1991 2,976 80.1 77.7 71.0 73.7 90.8 70.3 41.1 d
1992e1997 2,020 87.8 88.2 84.6 78.0 94.5 71.9 72.1 d
Group A streptococcus 1999e2002 145 99.4 98.7 d 63.9 d 59.3 d 100
2003e2005 198 100 100 d 84.3 d 75.3 d 100
Group B streptococcus 1999e2002 360 90.8 90.6 d 39.6 d 39.8 d 100
2003e2005 756 99.6 99.6 d 51.1 d 53.2 d 100
Non-A, B, D streptococci 1999e2002 494 89.3 87.9 d 72.0 d 68.3 d 100
2003e2005 706 99.3 99.7 d 84.9 d 82.1 d 100
Viridans group
streptococci
1999e2002 768 82.7 82.3 d 70.8 d 55.8 d 100
2003e2005 1,243 93.0 93.0 d 72.7 d 63.4 d 100
Enterococcus species 1985e1991 4,154 d 91.8 7.5 3.1 14.9 15.0 13.3 98.8
1992e1998 5,138 82.8 84.8 3.4 2.6 17.4 13.9 17.4 97.8
1999e2005 6,549 d 83.4 d d d d 36.1a 78.0
Enterococcus faecalis 1999e2005 376 d 97.6 d d d d 32.7a 94.8
Enterococcus faecium 1999e2005 345 d 16.3 d d d d 20.9a 72.5
a Susceptibility to high-dose gentamicin.
AMZ ampicillin; CCZ clindamycin; CZZ cefazolin; EZ erythromycin; GMZ gentamicin; OXZ oxacillin; PZ penicillin;
VAZ vancomycin.
134 W.-T. Lo et al.streptococci; and in S pneumoniae isolates (r<0.72 and
p< 0.05).
Figure 3 demonstrates the secular trends for cefotaxime/
ceftriaxone-resistant E coli and K pneumoniae, ceftazidime-
resistant P aeruginosa isolates (since 1988), imipenem-
resistant P aeruginosa isolates (since 1990), and imipenem-
resistant A baumannii isolates (since 1997). Resistance to
cefotaxime/ceftriaxone by E coli and K pneumoniae isolates
and resistance to imipenem by A baumannii isolates
increased significantly with time (r> 0.72 and p< 0.05).
Resistance to imipenembyA baumannii emerged in 2002 and
remained at 6.9e8.4% throughout the study periods. Resis-
tance to ceftazidime (9e23%) and imipenem (11e24%) by
P aeruginosa remained steady over the study periods.
Ciprofloxacin resistance of the major GNB from 1996 to
2005 is shown in Fig. 4. A baumannii and S marcescens
isolates were more resistant to ciprofloxacin from 1996
to 2005 than were other GNB isolates. E coli (from 1996 to
2005), E cloacae (from 1996 to 2005), and A baumannii
(from 1997 to 2005) resistance to ciprofloxacin increased
significantly with time (r> 0.72 and p< 0.05).
Discussion
Our results demonstrate that resistance to antimicrobial
agents increased rapidly during the past two decades inTaiwan. MRSA was first documented in Taiwan in the early
1980s.19 Since then, the prevalence of MRSA infections
markedly increased for both nosocomial- and community-
acquired infections.20e25 Several dominant clones are
prevalent in hospitals and in the community.20e25 A nat-
ionwide survey showed that MRSA isolates increased from
52% to 61% between 1998 and 2000.6 MRSA isolates
increased rapidly in our hospital from 33% in 1990, peaking
at 87.4% in 2000, and decreasing significantly thereafter
to 75.2% in 2004. The rate of MRSA in this report is higher
than in previously reported studies in Taiwan and other
countries.5e7,11,20,26 Although MRSA isolates are still largely
susceptible to vancomycin, the first S aureus isolate with
intermediate resistance to vancomycin (minimum inhibi-
tory concentration, 8 mg/mL) isolated from synovial fluid
and a knee wound from a patient with septic arthritis in our
hospital was reported in 2005.27 Furthermore, the increase
in MRSE in our report is worrisome because coagulase-
negative staphylococci are the leading cause of blood
stream infections, as revealed in the 1999 National Noso-
comial Infections Surveillance study.28
Taiwan has a relatively low prevalence of VRE (3e7% of
isolates),5e7,10,11 in contrast to the high prevalence of VRE
in United States intensive care units, where the rate was
about 28% from 2001 and 2004.29 The high prevalence of
VRE (22% in the third study period) in our analysis could be
Table 3 Antimicrobial susceptibility rates of common clinical gram-negative bacteria at Tri-Service General Hospital from 1985 to 2005
Pathogen Period Number
of isolates
Antimicrobial susceptibility (%)
AM CZ PIP CTX/CRO CAZa GM ANb IPMc SXTd CIP ATM NAd
Escherichia coli 1985e1991 7,672 23.4 57.6 d 98.4 99.2 74.2 95.1 99.5 57.2 d 99.0 88.7
1992e1998 6,533 21.9 58.2 d 97.6 98.0 64.0 96.7 99.8 44.3 81.2 96.8 76.2
1999e2005 14,322 19.4 38.7 d 80.9 84.6 65.5 96.3 99.9 38.9 67.1 84.6 43.7
Klebsiella pneumoniae 1985e1991 6,434 1.1 69.8 d 97.5 98.5 68.1 91.2 100 63.7 d 97.5 77.5
1992e1998 5,648 d 60.2 d 89.1 89.1 74.0 89.4 99.7 62.0 76.9 78.7 65.3
1999e2005 9,429 d 62.6 d 73.6 74.9 72.0 87.6 99.8 60.2 68.2 74.7 40.3
Proteus mirabilis 1985e1991 2,117 31.4 69.0 d 98.3 99.5 68.9 98.2 100 51.6 d 99.0 89.1
1992e1998 1,524 35.9 81.5 d 99.4 99.3 74.5 100 99.3 44.3 93.8 97.1 85.9
1999e2005 2,312 36.3 72.5 d 95.4 99.5 65.6 95.6 100 37.8 85.3 99.8 56.1
Enterobacter species 1985e1991 3,566 5.7 7.5 d 61.6 74.3 45.2 77.0 98.1 50.7 d 71.5 78.6
1992e1996 2,336 2.8 2.9 d 52.2 56.7 52.6 89.5 98.8 50.5 77.0 55.0 62.0
Enterobacter cloacae 1997e1998 925 0.5 0.5 d 49.4 48.7 42.9 84.1 100 44.3 80.7 46.7 39.5
1999e2005 3,477 0.3 0.5 d 46.9 56.5 59.5 77.7 100 51.0 64.2 46.4 28.4
Serratia marcescens 1985e1991 1,691 0.6 0.9 d 74.1 96.5 39.0 60.2 99.2 45.7 d 87.4 37.4
1992e1998 3,773 1.1 0 d 70.0 93.2 34.2 83.5 99.6 54.8 40.5 83.5 26.4
1999e2005 3,798 0.1 0.2 d 42.9 91.2 44.2 83.8 99.9 40.2 38.7 75.1 15.3
Pseudomonas aeruginosa 1985e1991 11,252 d d 73.6 7.1 85.8 49.6 71.9 87.4 d d 63.4 92.0
1992e1998 15,751 d d 83.0 17.8 84.2 51.6 81.0 83.6 d 71.3 64.4 d
1999e2005 17,338 d d 76.2 d 81.0 65.9 87.9 83.2 d 65.7 59.8 d
Acinetobacter species 1985e1991 3,210 7.6 2.4 53.3 13.9 74.2 40.5 63.7 96.0 50.8 d 12.4 73.4
1992e1996 4,227 2.9 1.4 53.6 27.5 65.2 30.2 60.6 97.3 48.3 89.0 8.2 77.4
Acinetobacter baumannii 1997e1998 2,071 1.0 d 42.4 25.3 54.8 21.3 43.6 98.0 30.7 52.2 7.4 16.7
1999e2005 9,021 0 d d 1.7 31.6 19.7 32.9 95.2 d 26.1 1.0 7.5
a During the first period (1985e1991), disk-susceptibility data of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter species, Serratia marcescens, Pseudomonas
aeruginosa, and Acinetobacter species were evaluated from 3,488; 2,857; 952; 1,379; 792; 5,219; and 1,378 isolates, respectively
b During the first period (1985e1991), disk-susceptibility data of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter species, Serratia marcescens, Pseudomonas
aeruginosa, and Acinetobacter species were evaluated from 5,480; 4,595; 1,512; 2,643; 1,254; 7,836; and 2,486 isolates, respectively
c During the first period (1985e1991), disk-susceptibility data of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter species, Serratia marcescens, Pseudomonas
aeruginosa, and Acinetobacter species were evaluated from 2,786; 2,321; 763; 975; 541; 3,864; and 982 isolates, respectively
d SXT and NA were only tested for isolates obtained from urine samples.
AMZ ampicillin; ANZ amikacin; ATMZ aztreonam; CAZZ ceftazidime; CIPZ ciprofloxacin; CROZ ceftriaxone; CTXZ cefotaxime; CZZ cefazolin; GMZ gentamicin; IPMZ imipenem;
NAZ nalidixic acid; PIPZ piperacillin; SXTZ trimethoprim/sulfamethoxazole.
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Figure 1. Secular trend of selected gram-positive bacterial isolates resistant to various antimicrobial agents at Tri-Service
General Hospital from 1985 to 2005. ERSPZ erythromycin-resistant Streptococcus pneumoniae; HLGREZ high-level gentamicin
resistant enterococci; MRSAZmethicillin-resistant Staphylococcus aureus; MRSEZmethicillin-resistant Staphylococcus
epidermidis; PNSSPZ penicillin-nonsusceptible Streptococcus pneumoniae; VREZ vancomycin-resistant enterococci.
136 W.-T. Lo et al.because of the policy of routinely screening every patient
admitted to the intensive care units in our hospital for VRE;
thus, enterococci isolates included in this report are colo-
nizing and infecting isolates. Additionally, a previous
nationwide study in Taiwan showed that the rate of high-
level gentamicin resistance among E faecalis and E faecium
isolates was 66% and 62%, respectively.6 The higher rates of
HLGRE (around 65e75%) in the present report could corre-
late with administration of aminoglycosides because they
are the second most frequently used antimicrobial category
in Taiwan hospitals.14,30
The prevalence of PNSSP increased rapidly from 0% in
1993 to very high levels of 73.3% in 2004 and 88.9% in 2005
in our hospital. Although our PNSSP rate was lower than
that reported for Vietnam where the PNSSP prevalence
was 92% among clinical isolates during the 2000e2001
period,8 we report the highest prevalence of PNSSP in
Taiwan.5,6,9,15 Hsueh31 reported a 16% decline in rate of0
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Figure 2. Secular trend of various streptococci resistant to
erythromycin at Tri-Service General Hospital from 1999 to 2005.
GASZ group A streptococcus; GBSZ group B streptococcus.PNSSP from the 1998e1999 period to 2001, after a 46%
decrease in total penicillin and other cephalosporin usage
in 2001 compared with 1999. However, we did not find such
a decreasing trend. In addition, we report a significantly
declining trend in erythromycin resistance in Groups A and
B streptococci; non-A, B, and D streptococci; and S pneu-
moniae from 1999 to 2005. During the period of 1999e2003,
Hsueh et al.16,31 also demonstrated a decline in erythro-
mycin consumption and resistance rates of Group A strep-
tococci, but a continued increase in erythromycin resistant
S pneumoniae was found. The relatively small numbers of
S pneumoniae isolates in our report could contribute to the
differing results between two hospitals.
A previous study in Taiwan conducted by Jean et al.32
stated that cefotaxime-resistant E coli (33.3%) and K pne-
umoniae isolates (58.4%) exhibited ESBL. In our hospital,
among ceftriaxone-resistant E coli and K pneumoniae
isolates tested in 2004, 27.5% and 58.2%, respectively,
exhibited the ESBL phenotype. In the Asia-Pacific region,
ESBL-producing isolates showed high levels of coresistance
to aminoglycosides, tetracycline, trimethoprim-sulfame-
thoxazole, and ciprofloxacin.33 Although all the ESBL-
producing isolates were susceptible to imipenem at our
hospital, indiscriminate use of imipenem could promote
imipenem resistance.32e35 Thus, establishment of alterna-
tive agents for use against ESBL producers is crucial at the
individual hospital level because interhospital variation of
these data occur.34
Ciprofloxacin was launched in Taiwan in 1991, and
a dramatic increase in the prescription of fluoroquinolones
in Taiwan has occurred thereafter.13 Sheng et al.13 reported
the rapid increase in ciprofloxacin-resistant E coli, Morga-
nella morganii, S marcescens, P aeruginosa, and E cloacae
in 1996e1997, following the widespread use ciprofloxacin in
Taiwan. Additionally, we also report a significantly
increasing trend in ciprofloxacin resistance over time for
E coli (1996e2005), E cloacae (1996e2005), and A baumannii
(1997e2005).
An effective strategy to limit the effects of increasing
high antimicrobial resistance must be multifaceted and
must include education of patients and physicians about
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Figure 3. Secular trend of selected gram-negative bacterial isolates resistant to various antimicrobial agents at Tri-Service
General Hospital from 1985 to 2005. CAZZ ceftazidime; CROZ ceftriaxone; CTXZ cefotaxime; IPMZ imipenem.
Antimicrobial resistance of bacteria 137appropriate antimicrobial use, use of effective infection
control practices to prevent transmission from infected to
uninfected patients, surveillance of antimicrobial resis-
tance and antimicrobial use, improved use of immuniza-
tion, and development of alternative therapies that would
circumvent the need for antimicrobial therapy.29,30,36 The
government policy of restricting antibiotic use for acute
respiratory tract infections without evidence of bacterial
infection in Taiwan in 2001 resulted in a decrease in the use
of penicillins, cephalosporins, and macrolides and also
reduced macrolide-resistant Group A streptococcus.16 In
addition, the hospital moved to new facilities with
a smaller proportion of intensive care units beds and wider
interbed spaces, which could have contributed to the
significant decrease in the rate of MRSA after 2000 and the
relatively low prevalence of imipenem-resistant A bau-
mannii in our hospital.
In conclusion, this 21-year study in a medical center in
northern Taiwan demonstrated significant changes in anti-
microbial resistance among major bacterial pathogens.0
10
20
30
40
50
60
70
80
90
100
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
C
ip
ro
flo
xa
ci
n
 r
es
ist
an
ce
 (%
)
Year
E. coli K. pneumoniae P. mirabilis
E. cloacae S. marcescens P. aeruginosa
A. baumannii
Figure 4. Secular trend of major gram-negative bacterial
isolates resistant to ciprofloxacin at Tri-Service General
Hospital from 1996 to 2005.Dissemination and feedback of these data to clinicians and
decision makers at our hospital and others is crucial to
improve antibiotic prescribing and to implement effective
infection control.
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